当前位置: X-MOL 学术J. Clin. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
Journal of Clinical Oncology ( IF 42.1 ) Pub Date : 2017-12-20 , DOI: 10.1200/jco.2017.73.8633
Harry Quon 1 , Neha Vapiwala 1 , Arlene Forastiere 1 , Erin B. Kennedy 1 , David J. Adelstein 1 , Holly Boykin 1 , Joseph A. Califano 1 , F. Chris Holsinger 1 , Brian Nussenbaum 1 , David I. Rosenthal 1 , Lillian L. Siu 1 , John N. Waldron 1
Affiliation  

Purpose The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on radiation therapy in oropharyngeal squamous cell carcinoma (OPSCC) that was determined to be relevant to the American Society of Clinical Oncology (ASCO) membership. After applying standard critical appraisal policy and endorsement procedures, ASCO chose to endorse the ASTRO guideline. Methods The ASTRO guideline was reviewed by ASCO content experts for clinical accuracy and by ASCO methodologists for developmental rigor. On favorable review, an ASCO Expert Panel was convened to review the guideline contents and recommendations. The ASCO guideline approval body, the Clinical Practice Guidelines Committee, approved the final endorsement. Results The ASCO Expert Panel determined that the ASTRO guideline recommendations, published in July 2017, are clear, thorough, and based upon the most relevant scientific evidence. ASCO endorsed the ASTRO guideline and added minor qualifying statements. Recommendations Recommendations for the addition of systemic therapy to definitive radiotherapy in the treatment of OPSCC, postoperative radiotherapy with and without systemic therapy following primary surgery of OPSCC, induction chemotherapy in the treatment of OPSCC, and the appropriate dose, fractionation, and volume regimens with and without systemic therapy in the treatment of OPSCC are outlined for a variety of disease stages and clinical scenarios. ASCO Endorsement Panel qualifying statements and minor modifications were made to the ASTRO recommendations. The staging system that is referenced in these guidelines is the American Joint Committee on Cancer Staging Manual, 7th edition. Additional information is available at: www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki .

中文翻译:

口咽鳞状细胞癌放射治疗:美国临床肿瘤学会认可美国放射肿瘤学会循证临床实践指南

目的 美国放射肿瘤学会 (ASTRO) 制定了关于口咽鳞状细胞癌 (OPSCC) 放射治疗的循证指南,该指南被确定为与美国临床肿瘤学会 (ASCO) 的会员资格相关。在应用标准的批判性评估政策和认可程序后,ASCO 选择认可 ASTRO 指南。方法 ASTRO 指南由 ASCO 内容专家的临床准确性审查和 ASCO 方法学家的发展严谨性审查。审核通过后,召开了 ASCO 专家小组对指南内容和建议进行审核。ASCO 指南批准机构,即临床实践指南委员会,批准了最终认可。结果 ASCO 专家小组确定,2017 年 7 月发布的 ASTRO 指南建议,清晰、彻底,并基于最相关的科学证据。ASCO 认可了 ASTRO 指南并添加了少量的合格声明。建议 建议 OPSCC 根治性放疗加全身治疗,OPSCC 初次手术后有或无全身治疗的术后放疗,OPSCC 治疗中的诱导化疗,以及适当的剂量、分次和容量方案,以及概述了针对各种疾病阶段和临床情况的 OPSCC 治疗中没有全身治疗的情况。ASCO 认可小组的资格声明和对 ASTRO 建议的细微修改。这些指南中引用的分期系统是美国癌症分期联合委员会手册,第 7 版。
更新日期:2017-12-20
down
wechat
bug